5hon MSN
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...
The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with ...
Truist Financial analyst Richard Newitter maintained a Hold rating on Medtronic (MDT – Research Report) on February 23 and set a price target ...
Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...
The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...
Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by ...
Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no ...
6d
GlobalData on MSNMedtronic stock down 5% as surgical unit offsets ablation and diabetes growthMedtronic posted a strong profit for Q3 of fiscal year 2025, though shares were down as its cardiac ablation product success ...
Shares of Medtronic ( MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device ...
The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available nationwide in the next few months.
3don MSN
Medtronic's stock is probably not a jaw-dropping bargain at these prices, but it's an excellent business at a reasonable value. It's safe to call Medtronic a solid buy, especially if you're a ...
The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results